Phenotype/Genotype Correlations in Movement Disorders
NCT00018889
Recruiting
The goal of this protocol is to identify families with inherited movement disorders and evaluate disease manifestations to establish an accurate clinical diagnosis by using newest technological advances and investigate the underlying molecular mechanisms. Studies of inherited movement disorders in large families with good genealogical records are especially valuable. Patients with diseases of known molecular basis will be genotyped in order to investigate phenotype/genotype correlation. Patients... Read More
Gender:
ALL
Ages:
Between 2 years and 100 years
Trial Updated:
05/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Movement Disorder
Register for Updates
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
NCT04774718
Recruiting
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
05/01/2025
Locations: Lucile Packard Children's Hospital, Palo Alto, California +32 locations
Conditions: ALK Fusion-positive Solid or CNS Tumors
Register for Updates
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
NCT05828069
Recruiting
This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form... Read More
Gender:
ALL
Ages:
Between 180 days and 22 years
Trial Updated:
05/01/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +99 locations
Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Register for Updates
Early Onset Colorectal Cancer Detection
NCT06342401
Recruiting
Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagnosed CRC cases and it stands as the first cause of cancer-related death in young men and the second for young women. This study aims to detect EOCRC with a non-invasive test, using a blood-based molecu... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/01/2025
Locations: City of Hope Medical Center, Duarte, California +12 locations
Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I, Colorectal Cancer Stage IV, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Neoplasms Malignant
Register for Updates
Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke
NCT06615973
Recruiting
Background: Stroke is the fifth leading cause of death in the United States. It is also a leading cause of disability. More than 70% of people who survive strokes have mental impairment or dementia. Medical factors, such as the severity of the stroke, affect whether a person will have mental impairment afterward. But social factors, such as education and ethnicity, seem to play a role as well. Researchers want to learn more about how social and lifestyle factors affect a person s chances of mai... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Stroke, Brain Disease, Vascular Diseases, Cerebrovascular Disorder
Register for Updates
A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants
NCT06941077
Recruiting
The purpose of this study is to evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/01/2025
Locations: Celerion, Inc, Tempe, Arizona
Conditions: Healthy Volunteers
Register for Updates
PET Imaging and Lymph Node Assessment of IRIS in People With AIDS
NCT02147405
Recruiting
Background: - Sometimes people with HIV, the virus that causes AIDS, can have new or worsening symptoms soon after starting HIV medications. Often these symptoms are caused by immune reconstitution inflammatory syndrome (IRIS). Researchers want to study why and how people develop IRIS and how best to prevent and treat it. Objectives: - To learn the causes and effects of IRIS,and how to best manage it. Eligibility: - Adults 18 and older with HIV and low CD4 counts,, about to start HIV medici... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Immune Reconstitution Inflammatory Syndrome
Register for Updates
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334
Recruiting
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +440 locations
Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
Register for Updates
A Study of Doxycycline to Treat Chlamydial Infection
NCT05840159
Recruiting
This is a Phase 4 blinded, randomized, active-controlled, non-inferiority trial. Final evaluable population will include a minimum 596 individuals: 298 women with confirmed urogenital chlamydia (CT) and 298 men with confirmed rectal chlamydia (CT). Approximately 664 participants will be enrolled to achieve a minimum 596 participants who contribute primary outcome data. Randomization will be stratified by study site and sex: 332 women and 332 men. Participants will be randomized 1:1 to a 3-day re... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
05/01/2025
Locations: University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama +6 locations
Conditions: Chlamydial Infection
Register for Updates
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
NCT06347796
Recruiting
The goal of this clinical trial is to test in moderately symptomatic chronic subdural hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an alternative to conventional open surgery. The main questions it aims to answer are: * Compared to open conventional surgery, does MMAE reduce the need for rescue surgery or deaths? * What is the safety of MMAE and conventional open surgery in these patients? Participants will be asked to: * Share their medical history a... Read More
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
05/01/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +32 locations
Conditions: Chronic Subdural Hematoma
Register for Updates
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325
Recruiting
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
05/01/2025
Locations: Sl0044 50058, Avondale, Arizona +128 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Characterization of Diseases With Salivary Gland Involvement
NCT02327884
Recruiting
Background: - Salivary glands in and around the mouth and throat make saliva. Salivary gland disorders can affect a person s quality of life. Studying people who have a disease that affects their salivary gland(s) may teach researchers about the disorders and their genetics. Objectives: - To study salivary gland diseases and disorders. To collect data and samples from people with salivary gland problems and their relatives. Eligibility: * People more than 4 years old who have or are suspect... Read More
Gender:
ALL
Ages:
Between 4 years and 100 years
Trial Updated:
05/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteer, Salivary Gland Disease, Sjogren's Syndrome
Register for Updates